Semaglutide and tirzepatide are the two most effective weight-loss medications ever brought to market, and for several years the comparison between them relied on cross-trial arithmetic: comparing a result from the STEP programme against a result from SURMOUNT, in different populations, under different protocols. That changed when the two drugs were finally tested against each other directly. This guide leads with that head-to-head data and then works through everything it does not settle.
Understanding the Basics
Both medications belong to a class called incretin mimetics. They copy hormones your gut releases after eating, which regulate blood sugar, slow how quickly the stomach empties, and reduce appetite. The difference between them is how many of those hormones they imitate.
Key Difference
Semaglutide targets only the GLP-1 receptor, while Tirzepatide is a dual agonist that targets both GLP-1 and GIP receptors. GIP appears to improve how efficiently fat tissue handles nutrients and may amplify the GLP-1 effect, which is the leading explanation for tirzepatide's larger results in clinical trials.
The Head-to-Head Trials
Two trials put these drugs in the same study, against each other, in the same population. They are the most important evidence in this comparison and they both favour tirzepatide.
SURMOUNT-5: weight loss (NEJM, 2025)
SURMOUNT-5 randomised adults with obesity and without diabetes to tirzepatide or semaglutide 2.4 mg, the full weight-management dose, for 72 weeks. Tirzepatide produced an average weight loss of 20.2% of body weight against 13.7% for semaglutide, or 22.8 kg versus 15.0 kg in absolute terms. Tirzepatide participants were more likely to reach every threshold the trial measured, including losses of at least 10%, 15%, 20% and 25%. Waist circumference fell further as well.
A 6.5 percentage point difference sounds modest until you convert it. For someone starting at 250 lbs, it is the difference between losing about 34 lbs and about 51 lbs. That gap is the single strongest argument for tirzepatide, and it is why the rest of this article is largely about the reasons someone might still choose semaglutide.
SURPASS-2: blood sugar (NEJM, 2021)
SURPASS-2 compared tirzepatide at 5 mg, 10 mg and 15 mg against semaglutide 1.0 mg in people with type 2 diabetes over 40 weeks. All three tirzepatide doses were non-inferior and then superior to semaglutide for A1C reduction. Even the lowest tirzepatide dose lowered A1C by 2.09% and produced 7.8 kg of weight loss.
One caveat worth carrying forward: serious adverse events were reported in 5% to 7% of tirzepatide patients versus 3% on semaglutide. The efficacy advantage was not free.
Weight Loss Efficacy
The table below combines the head-to-head result with each drug's own pivotal trial, so you can see both the direct comparison and the figures each was approved on.
| Metric | Semaglutide 2.4mg | Tirzepatide 15mg |
|---|---|---|
| Head-to-head, 72 weeks (SURMOUNT-5) | -13.7% (15.0 kg) | -20.2% (22.8 kg) |
| Own pivotal trial | -14.9% at 68 weeks (STEP 1) | -20.9% at 72 weeks (SURMOUNT-1) |
| Patients achieving 10%+ loss | ~69% | ~86% |
| Patients achieving 20%+ loss | ~36% | ~57% |
| A1C reduction | 1.5-2.0% | 1.9-2.6% |
Every figure here is an average across a trial population. The spread around those averages is wide in both directions, and roughly one in ten participants in these trials lost very little. If you want to see what these percentages mean for your own starting weight, the planner on our homepage converts them into pounds and a timeline.
Benefits Beyond Weight Loss
This is where the comparison reverses. Tirzepatide wins on the scale, but semaglutide has been studied in far more indications, and the results are the strongest argument for choosing it.
| Indication | Trial | Finding |
|---|---|---|
| Cardiovascular events | SELECT (semaglutide) | 20% reduction in major adverse cardiovascular events |
| Chronic kidney disease | FLOW (semaglutide) | 24% lower risk of major kidney events |
| Liver disease (MASH) | ESSENCE (semaglutide) | 36.8% had fibrosis improvement at 72 weeks |
| Knee osteoarthritis | STEP 9 (semaglutide) | WOMAC pain -41.7 points vs -27.5 on placebo |
| Obstructive sleep apnea | SURMOUNT-OSA (tirzepatide) | Apnea-hypopnea index reduced by up to ~63% |
Our trial-by-trial breakdown of GLP-1 benefits beyond weight loss covers each of these studies in detail, including the populations they enrolled and the claims the data does not support.
Side Effects Comparison
Both drugs share the same profile, dominated by gastrointestinal symptoms that peak in the days after each dose increase: nausea, vomiting, diarrhea, constipation and reduced appetite. Rarer but serious risks include pancreatitis and gallbladder disease, and both carry a boxed warning regarding thyroid C-cell tumours.
The claim that one is clearly gentler than the other does not survive contact with the data. In SURMOUNT-5, discontinuation due to adverse events was 6.1% on tirzepatide and 8.0% on semaglutide, a modest edge to tirzepatide, while trial discontinuation was identical at 1.6% in both arms. In SURPASS-2, serious adverse events ran higher on tirzepatide. The honest summary is that they are comparable, and that titration pace matters more than which drug you are on.
The lever most people are not told about: almost all GI side effects are dose-escalation effects. Staying at a tolerable dose for an extra four weeks before stepping up resolves the majority of cases, and it is a conversation to have with your prescriber rather than a reason to quit. See managing GLP-1 side effects for the practical approach.
Lean mass
Both drugs cause some loss of lean mass alongside fat, with estimates ranging from roughly 25% to 40% of total weight lost, trending higher at higher doses. Because tirzepatide drives more total loss, the absolute lean mass at stake is larger. Adequate protein, generally 1.2 to 1.6 grams per kilogram of body weight, plus consistent resistance training are the standard countermeasures and apply equally to both.
Dosing, Titration and Formats
Both are once-weekly subcutaneous injections titrated upward in four-week steps, which exist to limit side effects rather than to build effectiveness gradually.
| Stage | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Starting dose | 0.25 mg weekly | 2.5 mg weekly |
| Titration steps | 0.5, 1.0, 1.7 mg | 5, 7.5, 10, 12.5 mg |
| Maximum dose | 2.4 mg weekly | 15 mg weekly |
| Time to full dose | ~16-20 weeks | ~20-24 weeks |
| Oral option | Yes | No |
The oral option is now a real differentiator
The FDA approved oral semaglutide 25 mg, marketed as the Wegovy pill, as the first oral GLP-1 for chronic weight management, with a US launch in early January 2026. Rybelsus, at lower doses, remains the oral semaglutide approved for type 2 diabetes. Tirzepatide is injection-only.
For anyone with genuine needle aversion, that is no longer a minor footnote. It is a reason semaglutide may be the only viable option, and it did not exist as a weight-management choice a year ago.
Switching between them
Changing active ingredients calls for a new prescribing decision. A matching row in two dose charts does not establish equivalent treatment, and a larger milligram number does not tell you how much stronger the other medicine is.
The Wegovy and Zepbound prescribing information gives separate dosing instructions. Neither provides a milligram-for-milligram conversion between semaglutide and tirzepatide. Ask the prescriber to explain the proposed regimen using your prior response, side effects and any treatment gap.
Before using the new prescription, confirm when the old medicine ends and the new one begins. Do not overlap or alternate them yourself. Zepbound’s label advises against use with any GLP-1 receptor agonist; Wegovy’s label advises against use with other semaglutide products or other GLP-1 receptor agonists.
Read the Wegovy label and Zepbound label, then explore why the milligram numbers do not match and how to compare personal fit.
Switching guidance checked September 9, 2026.
Cost and Access
Without insurance, brand-name prices for the two are broadly comparable:
| Brand | Indication | Monthly Cost (Without Insurance) |
|---|---|---|
| Ozempic | Type 2 Diabetes | $900-$1,000 |
| Wegovy | Weight Management | $1,300-$1,400 |
| Mounjaro | Type 2 Diabetes | $1,000-$1,100 |
| Zepbound | Weight Management | $1,000-$1,100 |
Insurance coverage varies widely. Many plans cover these medications for type 2 diabetes but not for weight loss alone, and Medicare has historically excluded weight-loss drugs. Our insurance coverage guide covers the appeal routes that actually work.
In compounded form the two separate sharply. Compounded semaglutide from a 503B outsourcing facility starts near $99 per month, against roughly $299 for compounded tirzepatide. Of the providers we have reviewed, CoreAge Rx is our top recommendation at those prices, with US-licensed prescribers and no membership fee. That roughly threefold difference is, for many people, the decisive factor.
What Happens When You Stop
Neither drug is a course of treatment with a finish line, and this is the fact that should shape the choice more than any efficacy percentage.
STEP 1 participants regained roughly two-thirds of their lost weight within a year of stopping semaglutide. In SURMOUNT-4, participants switched to placebo after a 36-week tirzepatide lead-in regained about 14% of body weight over the following year, while those who stayed on the drug continued to lose. Blood pressure, blood sugar and lipid improvements track the weight, so they recede with it.
The practical consequence: the drug you can afford indefinitely will outperform the more effective drug you have to stop after eight months. That single consideration reverses the SURMOUNT-5 result for a large number of people.
Which One Should You Choose?
The head-to-head data gives tirzepatide the efficacy title. The choice still comes down to which trade-off matters most in your situation.
Consider Tirzepatide if:
- Maximum weight loss is the priority and cost is manageable
- You have a large amount to lose, where the 6.5 point gap compounds into a substantial number of pounds
- You have obstructive sleep apnea, the indication with tirzepatide's own outcome trial
- You have type 2 diabetes and need the larger A1C reduction
- Semaglutide has already plateaued below your goal
Consider Semaglutide if:
- Long-term affordability is the binding constraint, which for most people it is
- You have cardiovascular disease, chronic kidney disease, heart failure, liver disease or knee osteoarthritis, all of which have dedicated semaglutide outcome trials
- You want an oral option rather than a weekly injection
- Your goal is within reach of semaglutide's average result, roughly 14% of body weight
- You prefer the longer real-world safety record
Frequently Asked Questions
Which is better for weight loss, tirzepatide or semaglutide?
Tirzepatide, based on the only head-to-head trial. In SURMOUNT-5, published in the New England Journal of Medicine in 2025, tirzepatide produced an average weight loss of 20.2% versus 13.7% for semaglutide 2.4 mg over 72 weeks, and tirzepatide participants were more likely to reach every threshold measured, including 10%, 15%, 20% and 25% loss.
Is tirzepatide better for blood sugar too?
In SURPASS-2, the head-to-head trial in people with type 2 diabetes, tirzepatide at 5 mg, 10 mg and 15 mg was both non-inferior and superior to semaglutide 1.0 mg for A1C reduction. Tirzepatide 5 mg lowered A1C by 2.09%. Serious adverse events were somewhat more common in the tirzepatide arms, at 5% to 7% versus 3%.
Does tirzepatide have fewer side effects than semaglutide?
The side effect profiles are similar and both are dominated by gastrointestinal symptoms during titration. In SURMOUNT-5, discontinuation due to adverse events was 6.1% on tirzepatide and 8.0% on semaglutide, a modest edge to tirzepatide. In SURPASS-2, serious adverse events ran higher in the tirzepatide arms. Neither drug is clearly gentler across the board.
Is there a pill version of either medication?
Yes, for semaglutide. The FDA approved oral semaglutide 25 mg, marketed as the Wegovy pill, as the first oral GLP-1 for chronic weight management, with a US launch in early January 2026. Rybelsus is the lower-dose oral semaglutide approved for type 2 diabetes. Tirzepatide is injection-only.
Can I switch from semaglutide to tirzepatide?
A clinician may recommend a switch, but the Wegovy and Zepbound labels do not provide a milligram-for-milligram conversion between semaglutide and tirzepatide. Get an individualized prescription and clear timing instructions. The dose numbers alone cannot predict appetite changes, side effects or further weight loss.
What happens if I stop taking either one?
Weight returns. STEP 1 participants regained roughly two-thirds of their lost weight within a year of stopping semaglutide, and in SURMOUNT-4 those switched from tirzepatide to placebo regained about 14% of body weight over the following year while participants who continued kept losing. Both are treatments for a chronic condition rather than a course with an end date.
Which one is cheaper?
Semaglutide, in every format. Brand-name prices are broadly comparable, running roughly $900 to $1,400 per month without insurance, but in compounded form the gap is wide: compounded semaglutide starts near $99 per month against roughly $299 for compounded tirzepatide. Since the benefits depend on staying on treatment, that difference often matters more than the efficacy gap.
Does semaglutide have advantages tirzepatide does not?
Yes. Semaglutide has the deeper outcomes record, with dedicated trials in cardiovascular disease (SELECT), chronic kidney disease (FLOW), heart failure (STEP-HFpEF), liver disease (ESSENCE) and knee osteoarthritis (STEP 9). It has a longer real-world safety history, an oral formulation, and it is substantially cheaper. If a condition on that list applies to you, it is an argument for the drug studied in it.
The Bottom Line
SURMOUNT-5 settled the efficacy question: tirzepatide produces more weight loss than semaglutide, by a margin of roughly 6.5 percentage points over 72 weeks, and it wins at every threshold measured. If the only variable were pounds lost, the comparison would be over.
It is not the only variable. Semaglutide has been studied in five more indications, costs about a third as much in compounded form, and now comes as a pill. Because both drugs only hold their results while you keep taking them, the medication you can sustain for years matters more than the one that wins a 72-week trial.
For most people the sensible starting point is semaglutide, moving to tirzepatide if progress stalls short of the goal or if a specific indication argues for it. That is a decision to make with a prescriber who knows your history, not one to settle from a comparison table.